Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- DSP, Shionogi to Comarket Combination Drug of Irbesartan, Amlodipine
June 7, 2012
- Novartis Pharma Revises Package Insert for Hypertension Treatment Rasilez
June 7, 2012
- Mr Mark Swindell Appointed Head of Specialty Care: Pfizer Japan
June 7, 2012
- Teva Pharma’s Committee Compiles Report on Issues at Former Taiyo Pharmaceutical Factory
June 6, 2012
- Astellas to Collaborate with US Company to Develop Bombesin BB2 Receptor Antagonist
June 6, 2012
- Kyowa Kirin’s UK Subsidiary Acquires Global Commercial Rights to Cancer Pain Drug Except Japan and US
June 6, 2012
- Tivantinib Significantly Improves TTP in HCC Patients: Daiichi Sankyo
June 6, 2012
- Takeda Completes Acquisition of URL Pharma; to Enhance Gout Field
June 6, 2012
- Eisai Boosts Alliance with Subsidiaries to Develop Diagnostic Agents
June 5, 2012
- Volume Discounts Are Naturally Expected in Price Negotiations: President Otani of Ain Pharmaciez
June 5, 2012
- MTPC to Terminate Development of Novel Vitamin D Compound Lunacalcipol in US
June 5, 2012
- RaQualia Begins PI Study for 5-HT4 Partial Agonist in UK
June 5, 2012
- Eisai Files for Triple Formulation Packs Including Pariet for H. Pylori Eradication
June 4, 2012
- SymBio to Postpone Filing for Supplemental NDA of Treakisym for Indication of Aggressive NHL
June 4, 2012
- Janssen Research & Development Files NDA for MTPC’s SGLT-2 Canagliflozin in the US
June 4, 2012
- Sawai Ranked Forerunner Among Drug Makers to Sell 3 Major Generics: Pharmacist Survey
June 1, 2012
- Ono Pharmaceutical to Collaborate with UK Company in Research of Drug Targets for Allergic Diseases
June 1, 2012
- Taiho to Initiate Global PIII Trial for Anticancer Agent TAS-102 in June
June 1, 2012
- MicroBiopharm Japan Announces Joint R&D Agreement with Eisai in Search of Compounds Derived from Natural Substances
June 1, 2012
- “Some Aspects Might Have Been Overlooked” in Actavis Adaptation Scenario: ASKA President Yamaguchi
May 31, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…